Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

News Daily News

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Michael O'Riordan

June 07, 2018

News Conference News TCT 2016

RIBS VI: El SVB Absorb es Seguro en el Manejo de la Reestenosis Intra-stent pero No Supera al Stent Metálico Xience

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

TRANSFORM-OCT: 生物可吸收和耐久聚合物 DES 早期和晚期愈合率类似

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Curación Precoz y Tardía con SLF Bioreabsorbibles y de Polímero Duradero

Michael O'Riordan

November 02, 2016

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

October 12, 2016

News Daily News

PLATFORM: FFRCT-Guided Strategy in Suspected CAD ‘Durable’ Out to 1 Year

Michael O'Riordan

July 27, 2016

News Daily News

PLATFORM: Ante Sospecha de EAC la Estrategia de Guiado mediante FFRTC ‘Tiene una Duración’ de 1 Año

Michael O'Riordan

July 27, 2016

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.